Polymorphism of Matrix Metalloproteinases Genes MMP1, MMP2, MMP3, and MMP7 and the Risk of Varicose Veins of Lower Extremities

Shadrina, Alexandra S.; Сметанина, М. А.; Sevost’yanova, K. S.; Шевела, А. И.; Селиверстов, Е. И.; Захарова, Е. А.; Воронина, Е. Н.; Ilyukhin, E. A.; Золотухин, И. А.; Кириенко, А. И.; Филипенко, М. Л.

doi:10.1007/s10517-017-3871-2

Cited by 10 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the table "Polymorphic variants/mutations of candidate genes and their associations with chronic venous disease" shows not only the gene, the type of mutation/single nucleotide polymorphism (SNP) and the reference to the article, but also the sample size and the degree of this association, which is decisive for the significance of this association. In the studies performed in our laboratory, it has been shown that, for example, for polymorphic variants of genes AGGF1 (rs13155212, rs7704267) [13] , MTHFR (rs1801133) and MTR (rs1805087) [14] , no associations with the risk of VVD in ethnic Russians were found. There were also no associations found for regulatory SNPs of matrix metalloproteinase genes MMP1 (rs1799750), MMP2 (rs243865), MMP3 (rs3025058) and MMP7 (rs11568818) [15] , whereas the rare rs1800562 A allele in the HFE gene leading to the accumulation of iron in the patient's tissues [16] and polymorphic variants rs1035550 C>T and rs34221221 T>C of the transcription factor FOXC2 gene [17] were associated with an increased risk of VVD.…”

Section: Genetic Association Studies On Varicose Vein Pathogenesis-an Overviewmentioning

confidence: 91%

The genetic constituent of varicose vein pathogenesis as a key for future treatment option development

Сметанина¹,

Шевела²,

Gavrilov³

et al. 2021

View full text Add to dashboard Cite

This perspective focuses primarily on the fundamental part of phlebology, where most attention is paid to the genetic aspects of the pathogenesis of varicose vein disease and where the main breakthrough advances in this area of research are discussed. We propose a direction for further actions to replenish molecular genetic knowledge about the main drivers of pathological processes in varicose vein disease and to complete the creation of an entire picture of pathogenesis, which, in turn, may serve as a key for the development of treatment options in the future in order to translate research evidence into clinical practice.

show abstract

Section: Genetic Association Studies On Varicose Vein Pathogenesis-an Overviewmentioning

confidence: 91%

The genetic constituent of varicose vein pathogenesis as a key for future treatment option development

Сметанина¹,

Шевела²,

Gavrilov³

et al. 2021

View full text Add to dashboard Cite

show abstract

“…We must emphasize that after the visit of a Vascular Specialist the prescription of venoactive drugs and graduated compression stockings rose 3-fold. This clearly shows the importance of being taken in charge by a vascular specialist (6, [26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Delphi case: Sharing of clinical experiences for improvement in the treatment of chronic venous disease

Camporese

Aloi²,

Santoliquido³

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Chronic venous disease (CVD) is a common condition with major health consequences that is associated with poor long-term prognosis, significant socioeconomic impact, disabling symptoms, and reduced quality of life. To provide a novel evidence-based approach in the management of CVD, a consensus process (“Delphi Case”) following a first Delphi Consensus was conceived. With a real-life fashion analysis, a steering committee formed by 3 expert leaders on chronic venous disease drove a panel of 77 expert Italian angiologists/vascular surgeons along a collegial discussion, integrating data coming from the guidelines recommendations of different Vascular Scientific Societies with the consensus agreement statements gathered from the first Delphi Consensus, and with data coming from the discussion of few statements in which there was disagreement. From July 15 to October 16, 2020, demographic, anamnestic, objective, and therapeutic data coming from a total of 2,275 patients were collected by the experts panel using a predefined case report form. The results of this second consensus provided a real-life picture of CVD management in the Italian population and clearly showed that a tailored therapeutic approach together with an appropriate lifestyle (e.g., diet, physical activity, weight loss) must be considered as the milestones for the CVD-related signs and symptoms clinical improvement in daily clinical practice. An evaluation of the adherence and of the efficacy of the prescribed pharmacological and compressive treatment in a medium-long term follow-up of the study population has been planned as the last step of this course and will be object of a future final publication.

show abstract

“…In further agreement with advocating a more individualised approach to management of CVD, the specialists also found consensus on statement 10 regarding the utility of identifying genetic polymorphisms that may affect progression of CVD. Indeed, several polymorphisms have been identified that appear to stratify with disease, notably HFE p.C282Y as well as those in metalloproteases [57][58][59][60]. Other researchers have proposed that a genetic risk score might be useful in distinguishing patients at risk for more severe disease [61].…”

Section: Conservative Therapymentioning

confidence: 99%

Refining diagnosis and management of chronic venous disease: Outcomes of a modified Delphi consensus process

Aloi

Camporese

Izzo

et al. 2019

European Journal of Internal Medicine

View full text Add to dashboard Cite

Chronic venous disease (CVD) is a common condition with major health consequences that is associated with poor long-term prognosis, significant socioeconomic impact, disabling symptoms and reduced quality of life. To provide practical guidance for diagnosis and management of CVD, a Delphi panel of 5 experts in steering committee and 28 angiologists/vascular surgeons met with the major aim of providing a supplement for established national and international guidelines. A total of 24 statements were voted upon in two rounds, of which consensus was reached on 22 statements, indicating a high level of overall agreement. Consensus was reached on 7 of 8 statements relative to diagnosis (CEAP classification, diagnostic tools, QoL assessment, diagnostic imaging) and on 15 of 16 statements on management (conservative treatments, compressive therapy, pharmacological therapy, surgical treatment). The results of the consensus reached are discussed herein from which it is clear that diagnostic and management approaches utilising personalised therapies tailored to the individual patient should be favoured. While it is clear that additional studies are needed on many aspects of diagnosis and management of CVD, the present Delphi survey provides some key recommendations for clinicians treating CVD that may be useful in daily practice.

show abstract

Polymorphism of Matrix Metalloproteinases Genes MMP1, MMP2, MMP3, and MMP7 and the Risk of Varicose Veins of Lower Extremities

Cited by 10 publications

References 12 publications

The genetic constituent of varicose vein pathogenesis as a key for future treatment option development

The genetic constituent of varicose vein pathogenesis as a key for future treatment option development

Delphi case: Sharing of clinical experiences for improvement in the treatment of chronic venous disease

Refining diagnosis and management of chronic venous disease: Outcomes of a modified Delphi consensus process

Contact Info

Product

Resources

About